InsiderTrades.com logo

HLS Insider Trading

Insider Ownership Percentage: 0.37%
Insider Buying (Last 12 Months): C$9,277.00
Insider Selling (Last 12 Months): C$0.00

HLS Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at HLS Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

HLS Therapeutics Share Price & Price History

Current Price: C$4.91
Price Change: ▲ Price Increase of +0.01 (0.20%)
As of 12/4/2025 05:00 PM ET

This chart shows the closing price history over time for HLS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

HLS Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/18/2025Dawn EdinboroSenior OfficerBuy100C$4.95C$495.00700
12/24/2024Norma BeauchampDirectorBuy500C$3.91C$1,957.00500
12/12/2024John Lee Welborn Jr.DirectorBuy2,100C$3.25C$6,825.00
11/14/2024Norma BeauchampDirectorSell500C$3.31C$1,655.00
8/14/2024John Gordon HannaDirectorBuy1,200C$3.19C$3,828.00
5/15/2024Craig MillianDirectorBuy2,500C$2.90C$7,250.00
11/16/2023Craig MillianDirectorBuy5,000C$2.60C$13,000.00
11/15/2023Brian Thomas WalshSenior OfficerBuy1,000C$2.91C$2,910.00
11/10/2023Polar Asset Management Partners Inc.InsiderBuy20,000C$4.30C$86,000.00
5/19/2023Tim HendricksonSenior OfficerBuy2,500C$4.50C$11,250.00
See Full Table

SEC Filings (Institutional Ownership Changes) for HLS Therapeutics (TSE:HLS)

0.38% of HLS Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

HLS Therapeutics logo
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States and the Rest of the world.
Read More on HLS Therapeutics

Today's Range

Now: C$4.91
Low: C$4.86
High: C$4.92

50 Day Range

MA: C$5.33
Low: C$4.75
High: C$5.72

52 Week Range

Now: C$4.91
Low: C$3.20
High: C$5.77

Volume

8,544 shs

Average Volume

13,573 shs

Market Capitalization

C$153.56 million

P/E Ratio

N/A

Dividend Yield

4.30%

Beta

0.44368

Who are the company insiders with the largest holdings of HLS Therapeutics?

HLS Therapeutics' top insider investors include:
  1. Dawn Edinboro (Senior Officer)
  2. Norma Beauchamp (Director)
  3. Craig Millian (Director)
  4. John Gordon Hanna (Director)
  5. John Lee Welborn Jr (Director)
Learn More about top insider investors at HLS Therapeutics.